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Precision oncology uses genomic evidence to match
patients with treatment but often fails to identify all
patients who may respond. The transcriptome of
these ‘‘hidden responders’’ may reveal responsive
molecular states. We describe and evaluate a
machine-learning approach to classify aberrant
pathway activity in tumors, which may aid in hidden
responder identification. The algorithm integrates
RNA-seq, copy number, and mutations from 33
different cancer types across The Cancer Genome
Atlas (TCGA) PanCanAtlas project to predict aberrant
molecular states in tumors. Applied to the Ras
pathway, the method detects Ras activation across
cancer types and identifies phenocopying variants.
The model, trained on human tumors, can predict
response to MEK inhibitors in wild-type Ras cell
lines. We also present data that suggest that multiple
hits in the Ras pathway confer increased Ras activ-
ity. The transcriptome is underused in precision
oncology and, combined with machine learning,
can aid in the identification of hidden responders.
INTRODUCTION
Precision oncology matches cancer patients to specific thera-
pies based on genomic evidence, but it has benefited only a rela-
tively low proportion of cancer patients to date (Prasad et al.,
2016). While clinically promising, precision oncology lacks com-
plete and accurate matching strategies and fails to identify many172 Cell Reports 23, 172–180, April 3, 2018 ª 2018 The Author(s).
This is an open access article under the CC BY license (http://creativepatients that could be matched using alternative approaches
(Kumar-Sinha and Chinnaiyan, 2018). Cataloging transcriptome
measurements across thousands of tumors enables a sys-
tems-biology perspective into the downstream consequences
of molecular perturbation. Detecting these perturbations using
transcriptomic states can improve precision oncology efforts
toward more accurate and complete pairing of patients to effec-
tive treatments (Cieslik and Chinnaiyan, 2018).
In the largest uniformly processed cancer dataset to
date, The Cancer Genome Atlas (TCGA) PanCancerAtlas has
released multi-platform genomic measurements across thou-
sands of tumors from 33 different cancer types (Weinstein
et al., 2013). With this scale of data, researchers can build
and evaluate statistical models that stratify tumors based on
aberrant gene and pathway function. Previously, strategies
have been explored using expression signatures to stratify pa-
tients (Bild et al., 2006). Some strategies have used data from
individual cancer types. For example, gene expression signa-
tures in colon adenocarcinoma (COAD) and glioblastoma
(GBM) stratified tumors with aberrant KRAS and NF1 function,
respectively (Guinney et al., 2014; Way et al., 2017). Further-
more, data integration approaches incorporating pathway
connectivity, including PARADIGM, are used to characterize
pathway activity and infer gain- or loss-of-function events
(Vaske et al., 2010; Ng et al., 2012; Sokolov et al., 2016). An un-
supervised approach decomposing gene expression states in
cell lines to map pathway activity has been proposed (Kim
et al., 2017). Here, we introduce an elastic net penalized logistic
regression classifier to learn signatures of gene or pathway
alterations from gene expression assays of tumor biopsies
across cancer types. We applied our method across cancer
types to learn an independent, pan-cancer signature of
pathway aberration. Our method can be used to identifycommons.org/licenses/by/4.0/).
Figure 1. Framing the Algorithm and Inte-
gration Tasks
(A) RNA-seq data (X) is multiplied by a vector of
gene weights (w) where the optimization task is to
find the optimalw to correctly classify the pathway
status matrix (y). We train the model with the train
partition and evaluate performance on a held-out
test set.
(B) The status matrix, y, is constructed by inte-
grating mutations and copy number alterations
(CNA). We consider activating or loss-of-function
mutations and high copy number gain and deep
copy number loss for oncogenes and tumor-sup-
pressor genes, respectively. Black squares indi-
cate aberrant events. For the Ras classifier, we
used non-silent somatic mutations and high copy
gains in the oncogenes KRAS, NRAS, and HRAS.phenocopying variants and requires only gene expression data
for inference on new data. We apply our method to detect
Ras pathway activation pan-cancer.
The Ras pathway is frequently altered in many different cancer
types (De Luca et al., 2012).When the pathway is activated, often
by gain-of-function KRAS,NRAS, orHRASmutations or through
NF1 loss-of-function events, cells increase their translational
output, and unchecked cellular proliferation occurs (McCormick,
1989; Xu et al., 1990). Certain cancer types, such as pancreatic
adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM),
thyroid carcinoma (THCA), lung adenocarcinoma (LUAD), and
COAD are known to be largely driven by mutations in Ras
pathway genes (Goretzki et al., 1992; Omholt et al., 2003; Pao
et al., 2005; di Magliano and Logsdon, 2013). Additionally, muta-
tions in the Ras pathway have been observed to be early events
driving tumorigenesis and have also been associated with poor
survival and treatment resistance (Garcia-Rostan et al., 2003;
Vauthey et al., 2013; Dinu et al., 2014; Hsu et al., 2016). Because
the Ras pathway is ubiquitously misregulated, developing spe-
cific therapeutic targets is one of the National Cancer Institute’s
key initiatives. However, Ras is also notoriously difficult to
therapeutically target, and accurate detection of its malfunction
is paramount (Stephen et al., 2014).
The most direct method of assessing Ras activation is by tar-
geted sequencing of Ras. However, these methods would fail to
detect unknown variants in other genes that phenocopy Ras-
activating mutations. Detecting such tumors may enable more
patients to be targeted therapeutically. In the present study,
we describe our machine-learning approach that integrates
bulk RNA sequencing (RNA-seq), copy number, and mutationCdata from the PanCanAtlas. We apply
the method to Ras genes and demon-
strate that our method can detect Ras
activation pan-cancer. The classifier
also identifies NF1 phenocopying events
in TCGA and prioritizes Ras wild-type
cell lines that respond to MEK inhibitors.
Manually curated oncogenic variants in
Ras pathway genes were assigned higher
classification scores than variants withunknown significance. Our method can be applied to other can-
cer-associated genes and pathways as well. For example, the
DNA Damage Repair PanCanAtlas analysis working group
(AWG) applied this approach to detecting TP53 inactivation
(Knijnenburg et al., 2018).
RESULTS
Machine-Learning Models to Predict Pathway Activity
We developed a machine-learning approach to detect aberrant
pathway activity in tumors. The method integrated RNA-seq,
copy number, andmutation data. Themodels were trained using
tumors from TCGA PanCanAtlas, with a complete set of these
measurements, which included 9,075 tumors across 33 different
cancer types. The method is based on a logistic regression clas-
sifier framework regularized with an elastic net penalty. We used
RNA-seq as a measurement describing the expression state of a
tumor and trained the classifier to detect downstream gene
expression patterns consistent with aberrant pathway activity
(Figure 1A). The algorithm learned a combination of gene impor-
tance scores, or weights (w), that together learn to best separate
aberrant from wild-type expression patterns. As input during
training, tumors with any non-silent somatic variants in target
genes were included in the positive set (Figure 1B). We also
included copy number gains for oncogenes and deep copy num-
ber loss for tumor suppressor genes (Figure 1B). For complete
details about the model and training approach, refer to the
STAR Methods. In principle, this approach could be applied to
predict other gene or pathway events. Here, we applied the
method to classifying Ras activity.ell Reports 23, 172–180, April 3, 2018 173
Figure 2. Evaluating Machine-Learning Clas-
sification of Ras Activation
(A) Cancer-type-specific percentages of Ras aber-
ration by copy number gain and deleterious muta-
tion in KRAS, HRAS, or NRAS. The colored squares
indicate whether the cancer type was included in
model training.
(B) Predicting Ras pathway activation metrics.
The gray lines represent classifier predictions on a
randomly shuffled gene expression matrix. Left:
receiver operating characteristic (ROC) curve and
area under the ROC (AUROC) curve given for
training, testing, and cross-validation (CV) sets. The
dotted navy line represents a hypothetical random
classifier. Right: precision recall (PR) curve and
corresponding area under the PR (AUPR) curve for
each evaluation set.
(C) Sparse classifier coefficients indicate which
genes impact classifier performance. log10_mut
represents tumor-specific non-silent mutation rate.
(D) Cancer-type-specific performance for the pan-
cancer model compared to separate models trained
on each cancer type independently.
See also Figures S2 and S3.Detecting Ras Activation Pan-cancer
Wetrainedaclassifier todetect aberrantRasactivity in tumors, us-
ing knowledge of KRAS, HRAS, and NRAS mutations and copy
number gains (see Figure 1). These 3 core Ras genes differed
greatly in variant prevalence across cancer types. In the
PanCanAtlas, KRASmutations were widespread in PAAD (72%),
COAD (45%), rectum adenocarcinoma (READ, 42%), and LUAD
(31%), whileNRASmutations were common in SKCM (31%) (Fig-
ure S1A). We performed a differential expression analysis of
PanCanAtlas tumors, controlled for cancer type, comparing
wild-type against aberrant Ras tumors (Figure S1B; Data S1).
In the classifier, to enforce a more balanced class representa-
tion and to reduce performance metric inflation (Davis and Goa-
drich, 2006), we used samples from 16 of 33 cancer types for
training (Figure 2A). We also used the top 8,000most variably ex-
pressed genes by median absolute deviation (MAD) (see STAR
Methods for details). We then randomly held out 10%of the sam-
ples (n = 476) to create a test set. The test set was selected to
have the same proportion of cancer types and Ras statuses as
the training set. The training set consisted of the remaining
90% (n = 4,283), which included 3,374 Ras wild-type tumors
and 909 tumors with non-silent somatic Ras variants. Within
the training set, we performed 5-fold cross-validation (CV). We
report training (‘‘training’’), cross-validation (‘‘CV’’), and held-
out test set (‘‘testing’’) performance using these cancer types.
We also evaluated the final classifier on cancer types that were
initially filtered from training.
Overall, the classifier showed high performance, with an
area under the receiver operating characteristic (AUROC) curve174 Cell Reports 23, 172–180, April 3, 2018above 84% and an area under the preci-
sion recall (AUPR) curve above 63% in
the cross-validation and testing sets (Fig-
ure 2B). For the samples initially filtered
from training, we also observed reasonableperformance, with an AUROC curve of 75.2% and an AUPR
curve of 24.7%. Therefore, the classifier detected Ras activation
signal in tissues it was not exposed to during training. Applying
the final classifier to all 9,075 samples, we observed an 86.7%
AUROCcurve and a 61.2%AUPR curve.We provide Ras predic-
tion scores for each PanCancerAtlas sample in Data S2.
The Ras classifier consisted of automatically learned gene
weights, or importance scores. Training with an elastic net pen-
alty resulted in a sparse classifier, with only 185 genes contrib-
uting to classification. Genes and covariates with weights above
zero can be interpreted as being upregulated in tumors with acti-
vated Ras, while negative-weight genes are characteristic of tu-
mors with wild-type Ras (Figure 2C). The full classifier gene
weights are provided in Data S3. However, caution must be
exercised in interpreting these coefficients, as our elastic net
regularization approach induces sparsity, which means that
the solution represents a subset of genes associated with—
and, therefore, useful for identifying—Ras activation. A differen-
tial expression analysis of Ras aberrant to wild-type tumors
would reveal these downstream genes (Data S1).
Nevertheless, many of the classifier-implicated genes are
known modulators of the Ras/MAPK (mitogen-activated protein
kinase) pathway. For instance, high expression of ERRFI1
contributed to predicting tumors with activated Ras. ERRFI1 is
a tumor suppressor of various receptors in the Ras pathway
(Masoumi-Moghaddam et al., 2014). The top positive gene,
PBX3, is a transcription factor previously implicated in certain
astrocytomas (Ho et al., 2013b). The second top positive gene,
SPRY2, inhibits FGFR signaling and interacts with ERBB1. The
Figure 3. Cell-LinePredictionsofRasActivity
(A) Ras classifier trained on PanCanAtlas tumors
applied to a dataset of small airway epithelial cells
(GEO: GSE94937). The mutant cells included a
stably expressed KRAS G12V mutation.
(B) Ras classifier trained on PanCanAtlas tumors
applied to 737 cell lines from The Cancer Cell Line
Encyclopedia (CCLE). Cell lines with KRAS, HRAS,
or NRAS mutations are indicated in the right
boxes, and wild-type tumors are indicated in the
left boxes. Scores for cell lines with BRAF muta-
tions (green) and wild-type BRAF (gold) are also
shown.
(C and D) Drug activity area for (C) selumetinib
(AZD6244) and (D) PD-0325901 compared
against Ras classifier scores for 388 CCLE cell
lines with both gene expression and pharma-
cologic profiling data. Cell lines with mutant
(orange) or wild-type (blue) KRAS, HRAS, and
NRAS are indicated. The best fit lines, SE
estimates, correlation coefficients, and p values
are shown separately for cell lines with mutant
or wild-type Ras.negatively associated genes are indicative of expression profiles
of wild-type Ras tumors. For example,CDK13was themost pre-
dictive gene and is involved in regulating transcription, which
potentially indicates an alternative mechanism driving transcrip-
tional disruption in wild-type Ras tumors. We also compared
pan-cancer classification with classifiers trained independently
within each cancer type. Both the cancer-type-specific and
pan-cancer classifiers had variable performance across cancer
types, with the pan-cancer model outperforming the models
optimized within cancer types approximately half of the time
(Figure 2D).
Ras Classifier Benchmarking Analyses
Weperformed several analyses to evaluate the robustness of the
Ras classifier. A null model trained on a randomly shuffled gene
expression matrix performed with about 50% AUROC and 20%
AUPR in holdout test and cross-validation sets, which indicates
strong performance of the model over this baseline (Figures S2A
and S2B). We also assessed performance of the classifier for de-
tecting Ras mutations and Ras copy number gains separately.
Performance was similar, with the mutations-only model per-
forming better than the combined model and the copy-num-
ber-only model performing worst (Figure S2C). Our model was
robust to dropping KRAS, NRAS, and HRAS and 11 other Ras-
opathy genes from the gene expression matrix (Figure S2D).
Lastly, performance was not impacted by covariate information
(Figure S2E).
We also explored gene coefficient relationships across
models. The high-weight-positive genes in the copy-only model
included C12orf11 (ASUN),MRPS35, ERGIC2, and CMAS, all of
which are located on chromosome 12p near KRAS, which may
indicate artifacts of common copy-gain events and be a result
of low sample size in the positive-copy-only set (Figure S2F).
Gene coefficients were similar across models when dropping
different Ras pathway genes (Figure S2G). Lastly, we comparedour machine-learning approach to a differential expression anal-
ysis of Ras mutant versus wild-type tumors controlled by cancer
type. The differential expression scores aligned closely with the
learned Ras classifier coefficients but identified many more
genes than the sparse classifier (Figure S2H) (Data S1). In sum-
mary, the Ras classifier differed depending on data-type inclu-
sion but was robust to input genes in the expression matrix,
did not rely on covariate data, and included similar but fewer
genes than a differential expression analysis.
Detecting Ras Activation in Cell Lines
We sought to determine whether predictions from the Ras clas-
sifier trained with TCGA tumors generalized to cell lines. We
applied the classifier to two cell-line datasets. First, we applied
the classifier to 10 small-airway epithelial cell RNA-seq profiles
(GEO: GSE94937) (Kim et al., 2017). The set consisted of 4
wild-type profiles and 6 KRAS G12V-expressing mutant pro-
files. Our classifier correctly classified 9 out of 10 profiles and
ranked all mutant profiles higher than all wild-type profiles
(p = 1.16e2) (Figure 3A). Though the PanCanAtlas data do
not include gene-edited tumors that would allow us to directly
evaluate Ras oncogenicity, the cell lines from this independent
test set are induced to stably express a bona fide oncogenic
KRAS variant.
Next, we applied our Ras classifier to RNA-seq profiles from
737 different cell lines from the Cancer Cell Line Encyclopedia
(CCLE) with matched expression and mutation data (Barretina
et al., 2012) (Figure 3B). The Ras classifier assigned significantly
higher scores to Ras mutated (KRAS, HRAS, or NRAS) from Ras
wild-type cell lines (p = 6.35e36). Of the 393 cell lines predicted
to be wild-type, 357 were labeled wild-type (negative predictive
value = 90.8%). However, only 153 of 344 cell lines that were pre-
dicted to be Ras mutated were labeled Ras mutant (precision =
44.5%). In total, 510 of 737 (69.2%) cell lines were predicted
correctly. In this case, the low precision could indicate eitherCell Reports 23, 172–180, April 3, 2018 175
Figure 4. Ras Activation across Ras Variants and Alternative Ras Pathway Members
(A) Cross-validation area under the receiver operating characteristic curve for predictingNF1 inactivation. Within and pan-cancer models are classifiers trained to
detect NF1 inactivation. The Ras model is the classifier trained in Figure 2. The pan-cancer NF1 classifier is shown in Figure S3.
(B) Ras classifier scores for sampleswith oncogenic or unconfirmed variants inKRAS,HRAS, andNRAS. Variant oncogenicity designations are based on curation
(see STAR Methods).
(C and D) Ras classifier scores stratified by Ras activity (KRAS,NRAS,HRAS) status and number of (C) aberrant mutations or (D) copy number alterations in other
Ras pathway members. The two rows of numbers above each graph indicate number of samples in each group (top) and percentage of samples assigned to
active Ras (bottom).
See also Figure S3.that the classifier failed to generalize or that the classifier suc-
cessfully identified phenocopying events, which were negatives
from the point of view of evaluations but also what we aimed to
capture.
We sought to differentiate between these two possibilities
by using independent information that was not provided to
the classifier. First, we examined mutation status for BRAF,
a well-characterized oncogene downstream of Ras genes
(Davies et al., 2002). BRAF mutations that phenocopy Ras
would be counted as negatives and, if they were highly
ranked, would reduce the observed precision. Indeed, the
classifier assigned significantly higher scores to BRAF mutant
cell lines, compared to BRAF wild-type cell lines (p = 1.16e–
11) (Figure 3B). Of all 191 false-positives, 56 had BRAF muta-
tions (29.3%). The remaining false-positives indicated either
tumors incorrectly assigned or tumors that harbored other
phenocopying variants. Next, we tested CCLE pharmacolog-
ical response data to determine whether Ras classifier scores
were predictive of sensitivity to MEK inhibitors. We observed
a strong correlation of the Ras classifier scores with sensi-
tivity to two MEK inhibitors, selumetinib (AZD6244) and PD-
0325901 (Figures 3C and 3D). The correlation was primarily
driven by cell lines that were wild-type for Ras genes, impli-
cating several drug-sensitive cell lines that may have other-
wise been missed by direct sequencing of Ras genes. Taken176 Cell Reports 23, 172–180, April 3, 2018together, the evaluation of additional mutations and the drug
response data for Ras wild-type cell lines strongly suggested
that the low precision in this case was related to the identifica-
tion of phenocopying events.
Lastly, the classifier scored 34 cell lines harboring Ras muta-
tions as Ras wild-type. We observed that 22 of these 34 false-
negatives harbored variants annotated in the COSMIC database
(64%) (Forbes et al., 2017). Conversely, 144 of 152 true-positives
harbored COSMIC variants (95%), which is significantly higher
than the proportion in false-negatives, c2 = 26.1, degree of
freedom 1, p = 3.2e7. Therefore, our classifier detected signal
at variant level resolution. We provide mean classifier scores for
all nucleotide (Data S4) and amino-acid (Data S5) Ras variants
observed in the CCLE.
Other Ras Pathway Variants Phenocopy Ras Activation
The Ras classifier was able to detect NF1-loss events particu-
larly well in CNS tumors (GBM, low-grade glioma [LGG], and
pheochromocytoma and paraganglioma [PCPG]). Performance
was comparable to that of NF1 classifiers built using cancer-
type-specific and pan-cancer models (Figure 4A). These tumors
were not included in training the Ras classifier. Detection of
NF1-inactivating events was also improved in COAD, OV, and
uterine corpus endometrial carcinoma (UCEC), as compared
to NF1-specific classifiers (Figure 4A). The Ras classifier’s
performance predicting NF1 loss of function was comparable to
that of distinct pan-cancer models trained specifically to detect
NF1 loss-of-function events (Figure S3).
We applied the Ras classifier to curated variants in 38 core Ras
pathway genes, which consisted of 34 oncogenes and 4 tumor-
suppressor genes (Chakravarty et al., 2017; Sanchez-Vega et al.,
2018). We provide Ras classifier scores for all Ras pathway mu-
tations detected in PanCanAtlas tumors (Data S4 and Data S5).
We observed an enrichment of high scores in tumors with onco-
genic variants in KRAS,NRAS, andHRAS (Figure 4B). Scores for
oncogenic BRAF variants were also enriched (Figure S4A). How-
ever, we noted that BRAF V600E mutations in THCA were over-
whelmingly predicted to be Ras wild-type (Figure S4B). We
trained a classifier for which we removed both of the BRAF-
dominated cancer types (THCA and SKCM) (Figure S4C). In
this model, we observed that THCA BRAF V600E mutations
were predicted to have Ras activation, which aligns with previ-
ous understanding of BRAF function and our cell-line analysis
(Figure S4D).
Lastly, in wild-type samples for KRAS, NRAS, and HRAS (Fig-
ure 4C, blue bars), we observed that Ras classifier scores
increased after subsequent mutations in other pathway genes.
In samples with a KRAS, NRAS, or HRAS mutation (Figure 4C,
red bars), classifier scores did not increase after additional mu-
tations to other genes in the pathway. However, more copy num-
ber events in other Ras pathway genes led to lower Ras classifier
scores in Rasmutated samples (Figure 4D). These results poten-
tially suggest that multiple hits in Ras pathway genes outside of
Ras genes themselves may confer an increased Ras activation
phenotype.
DISCUSSION
Wedescribed amachine-learningmethod to detectmalfunction-
ing genes and pathways in cancer and applied ourmethod to de-
tecting Ras activation. The method has variable performance
across cancer types but is generally sensitive and specific over-
all, is generalizable to cell-line data, largely aligns with curated
variant oncogenicity, and identifies phenocopying events lead-
ing to activated Ras. The approach can be applied generally to
other genes and pathways.
The cell-line evaluation included accurately detecting isogenic
lines transfected to express activating KRAS mutations and
identifying CCLE cell lines with known Ras and BRAFmutations.
We also demonstrated that CCLE Ras classifier scores were
correlated with the drug activity of two MEK inhibitors (selumeti-
nib and PD-0325901). In clinical trials, selumetinib did not in-
crease overall survival in KRAS mutant advanced non-small-
cell lung cancer (NSCLC) patients (Ja¨nne et al., 2013, 2016).
PD-0325901 also failed to meet efficacy endpoints in KRAS
mutant NSCLC patients (Haura et al., 2010). Selumetinib and
PD-0325901 have also been tested acrossmany different cancer
types, including ovarian, thyroid, skin, hepatocellular, breast,
and colon cancers (Boasberg et al., 2011; Farley et al., 2013;
Ho et al., 2013a; Ja¨nne et al., 2016; O’Neil et al., 2011). Selume-
tinib has shown promising results in treating children with NF1
mutant plexiform neurofibromas (Dombi et al., 2016), while PD-
0325901 has shown efficacy in treating NF1 mutant neurofi-bromas in mouse- and human-derived malignant peripheral
nerve sheath xenografts (Jessen et al., 2013). Furthermore, the
classifier automatically learns similar gene coefficients of an
18-gene panel previously curated using a targeted differential
expression analysis to predict selumetinib sensitivity (Dry et al.,
2010). Overall, our results suggest a useful biomarker application
to potentially reveal hidden responders that may have otherwise
been missed by sequencing.
Our approach to detecting Ras activation is supervised and,
as with any supervised approach, is penalized by inaccurate la-
bels. We encountered this limitation when detectingBRAFmuta-
tions in THCA. BRAF mutations are known to activate ERK and
should not be classified as wild-type Ras (Oikonomou et al.,
2014). Our results suggest that, in situations with predicted con-
founding mutations, it may be best to withhold a cancer type
entirely during training. Withholding such data, as opposed to
re-building a new classifier post hoc that uses BRAF V600E mu-
tations as positive examples, may help to prevent a process of
classifier creep, in which the classifier is continually expanded
to improve metrics. Additionally, it is unclear how to best adjust
for hypermutated phenotypes, as these tumors are more likely to
have Ras mutations by chance. Unsupervised or semi-super-
vised methods to automatically retrieve gene expression signa-
tures may overcome labeling issues and may sidestep some of
the difficulties in modeling hypermutated tumors by first sepa-
rating sources of variation.
While mutual exclusivity analyses across pathways drives hy-
potheses and reveals etiological insights (Babur et al., 2015;
Mina et al., 2017), our findings suggest that, when multiple mu-
tations occur in Ras pathway genes, tumors exhibit a transcrip-
tional profile associated with increased Ras activity. This is
the opposite observation for copy number events, as more
events outside of KRAS, NRAS, and HRAS appear to confer
lower scores, which may indicate either some sort of dosage
response counteracting the effects of hyperactivation or alter-
native events that dampen accurate Ras classification. Further-
more, tumors harboring specific Ras pathway isoforms curated
by the PanCanAtlas Pathways AWG are generally predicted to
have higher scores than unconfirmed variants. We provide
scores for all observed somatic Ras variants for TCGA tumors
and CCLE cell lines at base-pair and amino-acid resolution
(Data S4 and Data S5) and present this resource for potential
follow-up study.
In conclusion, we presented a machine learning method to
predict Ras activity in individual bulk tumors using transcrip-
tomes. Our approach may sidestep requirements to profile mul-
tiple genomic measurements to detect Ras activation and iden-
tify more patients with activated Ras. Our approach can be used
as an additional method to improve precision oncology (Cieslik
and Chinnaiyan, 2018). Subclonal mutations may also prevent
accurate Ras classification by gene sequencing. Training classi-
fiers with single-cell RNA-seq data may enable the detection of
rare events and can help to characterize intratumor heterogene-
ity. As data increase in scale and algorithms are better con-
structed to model disease heterogeneity, the ability to research
downstream responses of pathway misregulation and identify
multi-model therapies targeting various vulnerabilities of individ-
ual tumors will improve.Cell Reports 23, 172–180, April 3, 2018 177
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METHOD DETAILS
Training machine learning classifiers to detect aberrant gene events
We integrated Illumina RNaseq, multi-center mutation calls (MC3), and GISTIC2.0 copy number threshold calls from The Cancer
Genome Atlas (TCGA) PanCanAtlas project to classify aberrant pathway function (Mermel et al., 2011). We downloaded TCGA data-
sets from the GenomeData Commons (GDC). In total, there were 9,075 tumors that weremeasured on all three platforms that passed
quality control filtering. We subset the gene expression matrix to the 8,000 most variably expressed genes by median absolute de-
viation (MAD), as genes that do not vary are unlikely to be useful for classification and to reduce training time. We dropped the target
genes of interest (e.g., KRAS,NRAS,HRAS orNF1) when training themodels to prevent themodel from potentially relying too heavily
on dosage-specific effects of these genes instead of the downstream response to their activation.We also removed the samples with
the highest mutation burden to remove potential false positives. We defined these samples based on five standard deviations above
the log10 total non-silent somatic mutation count per sample. Because we were interested in a balanced training set based on aber-
rant gene events, we further filtered samples to include only cancer-types with greater than 15 target gene events and a proportion of
negatives to positives no less than 5%.
Using this data, we trained a supervised elastic net penalized logistic regression classifier with stochastic gradient descent (Zou
and Hastie, 2005). Our model is trained on RNaseq gene expression (X) to predict gene status (Y) (see Figure 1). To control for tumors
with a hypermutator phenotype and potential tissue-specific expression patterns, we included cancer-type dummy variables and per
sample log10 mutation count in the model as covariates. We defined gold standard gene status using loss of function mutation andCell Reports 23, 172–180.e1–e3, April 3, 2018 e1
deep copy number losses for tumor suppressor genes and gain of function mutations and large copy number gains for oncogenes.
For simplicity and to reduce the requirement for extensive manual curation, we considered any non-silent mutation including inser-
tion-deletions in the gene body or mutations in splice site regions of target genes. For the specific focus of the paper, we integrated
gain of function mutation and copy number gains for the oncogenes (KRAS, NRAS, and HRAS), and loss of function and deep copy
number losses for the tumor suppressors (NF1). For example, if a tumor had a deleterious mutation or copy number amplification in
one of these genes, we considered the Ras status equal to one.
The objective of the classifier is to determine the probability a given sample (i) has a Ras event given the sample’s RNaseq mea-
surements (Xi). In order to achieve the objective, the classifier learns a vector of coefficients or gene-specific weights (w) that optimize
the following penalized logistic function.
Pðyi = 1 jXiÞ= fðXiwÞ= 1
1+ ewXi
negative loglikelihood = L= 
Xn
i = 1
yi logPðyi = 1 jXiÞ+ ð1 yiÞlogPðyi = 0 jXiÞ
w= argmin

L+a
X
rjw jrl

Where a and l are regularization and elastic net mixing hyperparameters that are only active during training, respectively. Using a
training set consisting of 90% of the full dataset, equally balanced for different proportions of included cancer-types and Ras status,
we performed cross validation over the hyperparameter grid: l = {0.15, 0.155, 0.16, 0.2, 0.25, 0.3, 0.4} and a = {0.1, 0.13, 0.15, 0.18,
0.2, 0.25, 0.3}. We used balanced 5-fold cross validation based on the highest cross-validation area under the receiver operating
characteristic (AUROC).
We trained the Ras classifier using optimal hyperparameters (l = 0.15 and a = 0.1) and assessed performance on training, testing
(held out 10% of data) and across 5-fold cross-validation intervals. In 5-fold cross-validation, the data are partitioned into five even
sets (balanced by Ras status and cancer-type). Four of the folds, called training intervals, are used to construct themodel. Themodel
is then evaluated on the fifth fold, which is called the evaluation fold. The reported training performance comes from the folds used for
training, while the cross-validation performance uses the evaluation fold. Therefore, performance on cross-validation intervals are the
predictions reported on the training set samples when they were included in the internal cross-validation evaluation fold. The full
model is reported in Data S3 and all resulting classification scores in Data S2 is the model learned from the training set alone.
Evaluating machine learning classifiers
We evaluated the pan-cancer classifiers in various ways. For every evaluation, we reported the AUROC and area under the precision-
recall (AUPR) curve. We also compared gene specific classifiers built using pan-cancer data to classifiers trained independently us-
ing only data from individual cancer-types. In these cases, each cancer-type specific model was optimized individually. We
compared how the pan-cancer model performed on individual cancer-types compared to individual cancer-type optimizations.
Additionally, we cataloged the performance of the Ras classifier to predict NF1 inactivation in various cancer-types. NF1 is a tumor
suppressor of Ras and we postulated that it would have similar downstream consequences that could be captured by the Ras clas-
sifier. Therefore, we performed the same procedure of filtering datasets and training pan and within cancer-type classifiers for NF1.
We compared these NF1 evaluations against the Ras classification. Lastly, we evaluated the Ras classifier on predicting aberrant
mutations of other genes and variants in the Ras pathway and in two different cell line datasets.
Classifier Benchmarking Analyses
Wedetermined the robustness of the classifier by evaluating performance under various input features and prediction tasks.We eval-
uated potential inflation of performance metrics by training a null model on a randomly shuffled input gene expression matrix. We did
not shuffle the covariate information or the y matrix. Performance on the random shuffling of genes, while maintaining the same ratio
of Ras mutations, provides insight into how the model would be expected to perform in a scenario lacking Ras activation signal. We
also performed the same shuffling and classifier testing procedure as internal negative controls in every pan-cancer model and report
ROC/PR curves and AUROC/AUPRs in each figure.
To assess value added in combining mutation and copy number data in the prediction task (altering the y matrix), we trained pan-
cancer classifiers with the same procedure described above to predict Ras mutations and Ras copy number gains separately. The
combined model presented here is the same model trained in Figure 2. To test the effect of dropping KRAS, HRAS, and NRAS from
the model (altering the X matrix), we trained models with the previously described procedure with the input gene expression matrix
without dropping Ras genes. We also tested a classifier after dropping 14 genes from the Expanded RASopathy Panel (Genetic
Testing Registry). The genes included BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NF1, NRAS, PTPN11, RAF1, SHOC2,
SOS1,SPRED1, andRIT1. For the two previous comparisons, we compared the learned gene expression coefficients to the classifier
trained in Figure 2. For the dropping genes analysis, we added back all dropped genes as zero weights. We also compared thee2 Cell Reports 23, 172–180.e1–e3, April 3, 2018
performance of gene expression-only and covariate-only models (altering the Xmatrix) to the combinedmodel presented in Figure 2.
The y matrix remained the same, but each model was trained on only a subset of the combined X matrix. The differentially expressed
genes visualized in Figure S2H were obtained from the differential expression analysis described below.
Differential Expression Analysis
We performed a differential expression analysis using the limma Bioconductor package (Ritchie et al., 2015). We adjusted the model
by cancer-type by including cancer-type indicator variables in the limma design matrix. We considered all 9,074 samples and 20,500
genes in this analysis. We zero-one normalized the input matrix by gene prior to fitting with limma.
Cell Line Validation
We applied the Ras classifier to two independent cell line datasets. The first dataset was generated by Kim et al. (2017) and was
deposited in the Gene Expression Omnibus (Edgar et al., 2002) with the identifier GEO: GSE94937. We used the preprocessed
form of the data from (Kim et al., 2017). We also used data from 737 cell lines from the CCLE that hadmatching RNaseq andmutation
data (Barretina et al., 2012). Of these 737, 708 also had variant level annotations. In order to apply the classifier to both cell-line data-
sets, we z-score normalized gene expression values and subset the data to classifier genes, independently. 177 out of 185 (96%) of
the features were in common to classifier genes in both datasets, so we proceeded to make predictions with this subset. In order to
apply the predictions, we used the following transformation:
s= fðXiwÞ= 1
1+ ewX
Where s is the classifier prediction, w is the gene weights, and X is the corresponding subset cell line gene expression matrix.
We used the CCLE pharmacologic profiling data, which measured the activity of 24 drugs across 504 CCLE cell lines
(CCLE_NP24.2009_profiling_2012.02.20.csv). Data were accessed from https://portals.broadinstitute.org/ccle/data (Barretina
et al., 2012).
Ras Pathway and Oncogenicity Curation
We used the PanCanAtlas Pathways Working Group definition of 38 core Ras pathway genes (Sanchez-Vega et al., 2018). We ob-
tained oncogenicity assignments for mutations in these genes using OncoKB (Chakravarty et al., 2017) and additional manual cura-
tion by the PanCanAtlas Pathways AWG. Themanual curation included referencing MutSig (Lawrence et al., 2013), hotspot analyses
(Chang et al., 2016), and GISTIC Peaks (Mermel et al., 2011).
QUANTIFICATION AND STATISTICAL ANALYSES
We performed all machine learning model training, testing, and evaluations using sci-kit learn (version 0.18.1) with python 3.5.2 (Pe-
dregosa et al., 2011). We processed data using a combination of pandas (version 0.20.3) and dplyr (version 0.7.1) and visualized re-
sults using a combination of seaborn (version 0.7.1), ggplot2 (version 2.2.1), and PathwayMapper (Bahceci et al., 2017). R packages
were run on R version 3.4.0. Please refer to the Key Resources Table and the available GitHub repository (https://github.com/
greenelab/pancancer) for full software version details.We evaluated all classifiers using AUROC and AUPR. The AUROC is a metric
describing the overall trade-off between true positive and false positive rates, while the AUPRmeasures precision against recall for a
given classifier. An AUROC of 0.5 constitutes random guessing. We describe specific filtering steps for each analysis in various pla-
ces in theMethod Details section of the STARMethods. We describe overall sample and gene filtering in the Training subsection. We
discuss additional gene filtering for evaluating all alternative genes in the Evaluation subsection. We set random seeds in all compu-
tational analyses in order to preserve reproducibility. We performed independent t tests with unequal variances when comparing
classifier scores for curated variants versus variants of unknown significance per Ras pathway gene. We performed the same test
comparing CCLE cell line Ras classifier scores for Ras wild-type versus Ras (KRAS, HRAS, or NRAS) mutant samples and for
Ras wild-type, BRAF wild-type versus Ras wild-type, BRAF mutant. Using the up to 388 cell lines with both gene expression and
pharmacology data measured, we fit linear regression models comparing drug activity versus Ras classifier scores for all 24 drugs
to Ras wild-type and Rasmutant cell lines individually. Using a Bonferroni adjusted p value (0.05 / (24 * 2) = 0.001), we implicated two
high correlated drugs (AZD6244 (Selumetinib) and PD-0325901). Selumetinib was tested on 387 cell lines while PD-0325901 was
tested on 388 cell lines. We also used a chi square test for proportions of Ras mutations annotated as COSMIC variants in true pos-
itives compared to false negatives with a null hypothesis that both sets of samples have the same proportion of COSMIC variants.
DATA AND SOFTWARE AVAILABILITY
All analytical results can be reproduced using the code available at https://github.com/greenelab/pancancer.There, we provide in-
structions to replicate the computing environment, download versioned data, and all scripts to reproduce the entire analysis pipeline.
The pipeline is modular and amendable to generate classifiers and predictions for any combination of genes, pathways, and TCGA
PanCanAtlas cancer-types. The source code has been deposited to Zenodo at https://doi.org/10.5281/zenodo.1186801.Cell Reports 23, 172–180.e1–e3, April 3, 2018 e3
